USA - New York Stock Exchange - NYSE:DVA - US23918K1088 - Common Stock
The current stock price of DVA is 113.98 USD. In the past month the price decreased by -5.1%. In the past year, price decreased by -26.13%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.62 | 101.06B | ||
| CI | THE CIGNA GROUP | 9.73 | 73.86B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 125.45 | 23.08B | ||
| LH | LABCORP HOLDINGS INC | 16.05 | 21.05B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.03 | 19.57B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.27B | ||
| HIMS | HIMS & HERS HEALTH INC | 63.54 | 7.81B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 37.01 | 6.81B | ||
| CHE | CHEMED CORP | 19.64 | 6.12B | ||
| RDNT | RADNET INC | 192.5 | 5.64B | ||
| OPCH | OPTION CARE HEALTH INC | 21.87 | 5.17B | ||
| WGS | GENEDX HOLDINGS CORP | 71.16 | 3.87B |
DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 76,000 full-time employees. The firm is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. The company also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
DAVITA INC
2000 16th St
Denver COLORADO 80202 US
CEO: Javier J. Rodriguez
Employees: 76000
Phone: 13105362668
DaVita, Inc. engages in the provision of medical care services. The company is headquartered in Denver, Colorado and currently employs 76,000 full-time employees. The firm is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. The company also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
The current stock price of DVA is 113.98 USD. The price decreased by -0.38% in the last trading session.
DVA does not pay a dividend.
DVA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
The PE ratio for DAVITA INC (DVA) is 12.35. This is based on the reported non-GAAP earnings per share of 9.23 and the current share price of 113.98 USD.
DAVITA INC (DVA) has a market capitalization of 8.05B USD. This makes DVA a Mid Cap stock.
You can find the ownership structure of DAVITA INC (DVA) on the Ownership tab.
ChartMill assigns a fundamental rating of 5 / 10 to DVA. DVA has an excellent profitability rating, but there are concerns on its financial health.
Over the last trailing twelve months DVA reported a non-GAAP Earnings per Share(EPS) of 9.23. The EPS increased by 3.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.8% | ||
| ROA | 4.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
17 analysts have analysed DVA and the average price target is 141.36 USD. This implies a price increase of 24.02% is expected in the next year compared to the current price of 113.98.
For the next year, analysts expect an EPS growth of 12.69% and a revenue growth 5.89% for DVA